A Phase III Trial of Recombinant Human Apo-2 Ligand for Injection

Phase 3 Unknown 417 enrolled Shanghai Gebaide Biotechnology Co., Ltd.

RandomizedParallel-groupTriple-blindTreatment

Summary

The trial is to evaluate the efficacy and safety of recombinant human Apo-2 ligand in treating patients with advanced retreated non-small cell lung cancer

Timeline

Start: 2016-10
Primary completion: 2017-10
Completion: 2018-06

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Dulanermin	Protein / enzyme biologic	150 ug/kg	Intravenous

A Phase III Trial of Recombinant Human Apo-2 Ligand for Injection

Summary

Timeline

Drugs

Indications